Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity
Weight-loss surgery outperforms semaglutide injections for preventing major heart events in large matched groups, particularly for heart failure prevention.
In propensity-matched cohorts (>18,000 patients from TriNetX), metabolic/bariatric surgery was associated with significantly lower composite cardiovascular events than semaglutide therapy in both non-T2DM (HR 0.402) and T2DM (HR 0.421) groups; heart failure showed the greatest relative benefit (HR 0.29-0.35 favoring surgery). This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- retrospective_cohort_propensity_matched
- Category
- cardiovascular_metabolic
- Maturity
- Validated
- Journal
- Endocrine Practice
Why it surfaced
Timely large-cohort comparative effectiveness data on semaglutide vs. bariatric surgery with cardiovascular endpoints; directly relevant to treatment hierarchy discussions and formulary decision-making as GLP-1 RA use expands. TriNetX propensity matching is real-world evidence of moderate quality (not RCT), limiting causal inference.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.